A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Amplimmune
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT02013804
First received: December 12, 2013
Last updated: October 19, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
No publications provided by MedImmune LLC

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):